Haemonetics Stock Buy Hold or Sell Recommendation
| HAE Stock | USD 87.89 0.64 0.72% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Haemonetics is 'Hold'. Macroaxis provides Haemonetics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding HAE positions.
Check out Haemonetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide. Note, we conduct extensive research on individual companies such as Haemonetics and provide practical buy, sell, or hold advice based on investors' constraints. Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Haemonetics |
Execute Haemonetics Buy or Sell Advice
The Haemonetics recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Haemonetics. Macroaxis does not own or have any residual interests in Haemonetics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Haemonetics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | OK | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Haemonetics Trading Alerts and Improvement Suggestions
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: ZBH Stock Gains From FDA Nod for Oxford Cementless Partial Knee |
Haemonetics Returns Distribution Density
The distribution of Haemonetics' historical returns is an attempt to chart the uncertainty of Haemonetics' future price movements. The chart of the probability distribution of Haemonetics daily returns describes the distribution of returns around its average expected value. We use Haemonetics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Haemonetics returns is essential to provide solid investment advice for Haemonetics.
| Mean Return | 0.24 | Value At Risk | -2.1 | Potential Upside | 4.24 | Standard Deviation | 2.19 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Haemonetics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Haemonetics Stock Institutional Investors
| Shares | Schroder Investment Management Group | 2024-06-30 | 925.6 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 834 K | Westfield Capital Management Company, Lp | 2024-09-30 | 823.7 K | Btim Corp | 2024-09-30 | 809.6 K | Royal Bank Of Canada | 2024-06-30 | 791.7 K | Fmr Inc | 2024-09-30 | 774.5 K | Fisher Asset Management, Llc | 2024-09-30 | 689.5 K | Franklin Resources Inc | 2024-09-30 | 682 K | Sg Capital Management, Llc | 2024-09-30 | 643.4 K | Blackrock Inc | 2024-06-30 | 6 M | Vanguard Group Inc | 2024-09-30 | 5.2 M |
Haemonetics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (84.7M) | (38.9M) | 24.3M | 30.8M | (60.1M) | (57.1M) | |
| Change In Cash | (32.0M) | 55.0M | 67.2M | 25.0M | (105.7M) | (100.4M) | |
| Free Cash Flow | 109.5M | 71.8M | 75.8M | 162.9M | 115.5M | 121.2M | |
| Depreciation | 110.3M | 84.3M | 97.7M | 93.3M | 97.2M | 54.3M | |
| Other Non Cash Items | 42.5M | (919K) | 16.9M | 8.5M | 24.4M | 20.1M | |
| Capital Expenditures | 48.8M | 37.0M | 96.5M | 110.2M | 66.3M | 54.3M | |
| Net Income | 76.5M | 79.5M | 43.4M | 115.4M | 117.6M | 123.4M | |
| End Period Cash Flow | 137.3M | 192.3M | 259.5M | 284.5M | 178.8M | 138.4M | |
| Change To Netincome | 64.0M | 4.7M | 46.3M | 36.2M | 41.6M | 40.4M | |
| Change Receivables | 18.9M | 44.1M | (35.0M) | (24.4M) | (28.1M) | (26.7M) | |
| Net Borrowings | 31.9M | 370.7M | (17.5M) | 269.3M | 309.6M | 325.1M | |
| Investments | (57.2M) | (425.4M) | (86.3M) | (143.8M) | (322.4M) | (306.3M) |
Haemonetics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Haemonetics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Haemonetics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Haemonetics stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.11 | |
β | Beta against Dow Jones | 1.03 | |
σ | Overall volatility | 2.23 | |
Ir | Information ratio | 0.05 |
Haemonetics Volatility Alert
Haemonetics has relatively low volatility with skewness of 1.93 and kurtosis of 7.09. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Haemonetics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Haemonetics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Haemonetics Fundamentals Vs Peers
Comparing Haemonetics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Haemonetics' direct or indirect competition across all of the common fundamentals between Haemonetics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Haemonetics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Haemonetics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Haemonetics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Haemonetics to competition |
| Fundamentals | Haemonetics | Peer Average |
| Return On Equity | 0.14 | -0.31 |
| Return On Asset | 0.0588 | -0.14 |
| Profit Margin | 0.09 % | (1.27) % |
| Operating Margin | 0.16 % | (5.51) % |
| Current Valuation | 5.37 B | 16.62 B |
| Shares Outstanding | 50.22 M | 571.82 M |
| Shares Owned By Insiders | 0.89 % | 10.09 % |
| Shares Owned By Institutions | 99.11 % | 39.21 % |
| Number Of Shares Shorted | 4.58 M | 4.71 M |
| Price To Earning | 50.35 X | 28.72 X |
| Price To Book | 5.06 X | 9.51 X |
| Price To Sales | 3.27 X | 11.42 X |
| Revenue | 1.31 B | 9.43 B |
| Gross Profit | 530.77 M | 27.38 B |
| EBITDA | 265.58 M | 3.9 B |
| Net Income | 117.56 M | 570.98 M |
| Cash And Equivalents | 284.47 M | 2.7 B |
| Cash Per Share | 4.79 X | 5.01 X |
| Total Debt | 807.79 M | 5.32 B |
| Debt To Equity | 1.12 % | 48.70 % |
| Current Ratio | 2.73 X | 2.16 X |
| Book Value Per Share | 17.44 X | 1.93 K |
| Cash Flow From Operations | 181.75 M | 971.22 M |
| Short Ratio | 6.74 X | 4.00 X |
| Earnings Per Share | 2.41 X | 3.12 X |
| Price To Earnings To Growth | 1.61 X | 4.89 X |
| Target Price | 110.8 | |
| Number Of Employees | 3.66 K | 18.84 K |
| Beta | 0.32 | -0.15 |
| Market Capitalization | 4.45 B | 19.03 B |
| Total Asset | 2.2 B | 29.47 B |
| Retained Earnings | 360.46 M | 9.33 B |
| Working Capital | 468.52 M | 1.48 B |
Note: Acquisition by Stewart Strong of 6313 shares of Haemonetics at 95.73 subject to Rule 16b-3 [view details]
Haemonetics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Haemonetics . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Haemonetics Buy or Sell Advice
When is the right time to buy or sell Haemonetics? Buying financial instruments such as Haemonetics Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Haemonetics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Realty Funds Thematic Idea Now
Realty Funds
Funds or Etfs investing in real estate backed instruments or issues backed by different types of commercial properties. The Realty Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Realty Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Haemonetics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share 26.77 | Quarterly Revenue Growth 0.086 | Return On Assets 0.0588 |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.